First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | https://doi.org/10.1590/1516-3180.2021.0434.R1.22022022 http://hdl.handle.net/1843/60534 http://orcid.org/0000-0003-2550-7249 http://orcid.org/0000-0002-5528-0658 http://orcid.org/0000-0001-9411-7493 http://orcid.org/0000-0003-0138-9401 http://orcid.org/0000-0003-4024-0108 http://orcid.org/0000-0002-0210-0721 http://orcid.org/0000-0002-5880-5261 |
Resumo: | BACKGROUND: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects multiple joints. It is associated with psoriasis and treated with synthetic and biologic drugs. OBJECTIVE: The objective of this study was to assess the outcomes of patients who received biologic therapy with tumor necrosis factor (TNF) inhibitors in terms of effectiveness, safety, functionality, and quality of life. DESIGN AND SETTING: A prospective observational study was performed at a single center in Belo Horizonte, Brazil. METHODS: Patients with PsA who received their first TNF inhibitor treatment were followed up for 12 months. Disease activity was measured using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Clinical Disease Activity Index (CDAI). Functionality was measured using the Health Questionnaire Assessment (HAQ), and quality of life was evaluated using the European Quality of Life Five Dimensions (EQ-5D). Multiple linear regression was used to identify predictors of the clinical response at 12 months. RESULTS: A total of 143 patients treated with adalimumab or etanercept were evaluated. Most of the clinical measures were significantly improved at 12 months. However, 31%–51% of the patients did not achieve good clinical control. No differences were observed between adalimumab and etanercept, except for poor functionality at 12 months among patients treated with etanercept. The main predictors of a worse clinical response were female sex, etanercept use, poor functionality, or lower quality of life at baseline. The main adverse reactions were alopecia, headache, injection site reaction, sinusitis, flu, dyslipidemia, and infections. CONCLUSION: TNF inhibitor therapy was effective and safe. However, despite improvements in clinical measures, most patients did not achieve satisfactory control of the disease. |
id |
UFMG_f37669e7cc02a3abb6a17c333164aeeb |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/60534 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
2023-11-06T20:49:44Z2023-11-06T20:49:44Z20221406787797https://doi.org/10.1590/1516-3180.2021.0434.R1.220220221806-9460http://hdl.handle.net/1843/60534http://orcid.org/0000-0003-2550-7249http://orcid.org/0000-0002-5528-0658http://orcid.org/0000-0001-9411-7493http://orcid.org/0000-0003-0138-9401http://orcid.org/0000-0003-4024-0108http://orcid.org/0000-0002-0210-0721http://orcid.org/0000-0002-5880-5261BACKGROUND: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects multiple joints. It is associated with psoriasis and treated with synthetic and biologic drugs. OBJECTIVE: The objective of this study was to assess the outcomes of patients who received biologic therapy with tumor necrosis factor (TNF) inhibitors in terms of effectiveness, safety, functionality, and quality of life. DESIGN AND SETTING: A prospective observational study was performed at a single center in Belo Horizonte, Brazil. METHODS: Patients with PsA who received their first TNF inhibitor treatment were followed up for 12 months. Disease activity was measured using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Clinical Disease Activity Index (CDAI). Functionality was measured using the Health Questionnaire Assessment (HAQ), and quality of life was evaluated using the European Quality of Life Five Dimensions (EQ-5D). Multiple linear regression was used to identify predictors of the clinical response at 12 months. RESULTS: A total of 143 patients treated with adalimumab or etanercept were evaluated. Most of the clinical measures were significantly improved at 12 months. However, 31%–51% of the patients did not achieve good clinical control. No differences were observed between adalimumab and etanercept, except for poor functionality at 12 months among patients treated with etanercept. The main predictors of a worse clinical response were female sex, etanercept use, poor functionality, or lower quality of life at baseline. The main adverse reactions were alopecia, headache, injection site reaction, sinusitis, flu, dyslipidemia, and infections. CONCLUSION: TNF inhibitor therapy was effective and safe. However, despite improvements in clinical measures, most patients did not achieve satisfactory control of the disease.FUNDAMENTO: A artrite psoriática (APs) é uma doença inflamatória crônica que afeta múltiplas articulações. Está associada à psoríase e tratada com medicamentos sintéticos e biológicos. OBJETIVO: O objetivo deste estudo foi avaliar os resultados de pacientes que receberam terapia biológica com inibidores do fator de necrose tumoral (TNF) em termos de eficácia, segurança, funcionalidade e qualidade de vida. PROJETO E LOCAL: Um estudo observacional prospectivo foi realizado em um único centro em Belo Horizonte, Brasil. MÉTODOS: Pacientes com AP que receberam seu primeiro tratamento com inibidor de TNF foram acompanhados por 12 meses. A atividade da doença foi medida usando o Índice de Atividade da Doença da Espondilite Anquilosante de Bath (BASDAI) e o Índice de Atividade Clínica da Doença (CDAI). A funcionalidade foi medida por meio do Health Questionnaire Assessment (HAQ) e a qualidade de vida foi avaliada por meio do European Quality of Life Five Dimensions (EQ-5D). A regressão linear múltipla foi utilizada para identificar preditores da resposta clínica aos 12 meses. RESULTADOS: Foram avaliados 143 pacientes tratados com adalimumabe ou etanercepte. A maioria das medidas clínicas melhorou significativamente em 12 meses. No entanto, 31% a 51% dos pacientes não alcançaram um bom controle clínico. Não foram observadas diferenças entre o adalimumabe e o etanercepte, exceto pela baixa funcionalidade aos 12 meses entre os pacientes tratados com etanercepte. Os principais preditores de pior resposta clínica foram sexo feminino, uso de etanercepte, baixa funcionalidade ou menor qualidade de vida no início do estudo. As principais reações adversas foram alopecia, cefaleia, reação no local da injeção, sinusite, gripe, dislipidemia e infecções. CONCLUSÃO: A terapia com inibidores de TNF foi eficaz e segura. Contudo, apesar das melhorias nas medidas clínicas, a maioria dos pacientes não alcançou um controle satisfatório da doença.CNPq - Conselho Nacional de Desenvolvimento Científico e TecnológicoFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas GeraisengUniversidade Federal de Minas GeraisUFMGBrasilFAR - DEPARTAMENTO DE FARMÁCIA SOCIALMED - DEPARTAMENTO DE APARELHO LOCOMOTORMED - DEPARTAMENTO DE CLÍNICA MÉDICASao Paulo Medical JournalArtrite psoriásicaPesquisa comparativa da efetividadeAdalimumabEtanercepteEstudo observacionalDiferença mínima clinicamente importanteArthritis, psoriaticComparative effectiveness researchAdalimumabEtanerceptObservational study [publication type]Minimal clinically important differenceFirst-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational studyTerapia biológica de primeira linha com inibidores do fator de necrose tumoral para artrite psoriática: um estudo observacional prospectivoinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://www.scielo.br/j/spmj/a/YpDWKwF74J7LgSxLf8DcLZD/?lang=en#Michael Ruberson Ribeiro da SilvaJéssica Barreto Ribeiro Dos SantosAdriana Maria KakehasiAlessandra Maciel AlmeidaPedro Ricardo Kömel PimentaJuliana Alvares TeodoroFrancisco de Assis Acurcioapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/60534/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALFirst-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis_ a prospective observational study.pdfFirst-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis_ a prospective observational study.pdfapplication/pdf320834https://repositorio.ufmg.br/bitstream/1843/60534/2/First-line%20biologic%20therapy%20with%20tumor%20necrosis%20factor%20inhibitors%20for%20psoriatic%20arthritis_%20a%20prospective%20observational%20study.pdf4b4709a03b6447669df31e2cc2ba7aa7MD521843/605342023-11-06 17:49:44.802oai:repositorio.ufmg.br:1843/60534Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-11-06T20:49:44Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.pt_BR.fl_str_mv |
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study |
dc.title.alternative.pt_BR.fl_str_mv |
Terapia biológica de primeira linha com inibidores do fator de necrose tumoral para artrite psoriática: um estudo observacional prospectivo |
title |
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study |
spellingShingle |
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study Michael Ruberson Ribeiro da Silva Arthritis, psoriatic Comparative effectiveness research Adalimumab Etanercept Observational study [publication type] Minimal clinically important difference Artrite psoriásica Pesquisa comparativa da efetividade Adalimumab Etanercepte Estudo observacional Diferença mínima clinicamente importante |
title_short |
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study |
title_full |
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study |
title_fullStr |
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study |
title_full_unstemmed |
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study |
title_sort |
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study |
author |
Michael Ruberson Ribeiro da Silva |
author_facet |
Michael Ruberson Ribeiro da Silva Jéssica Barreto Ribeiro Dos Santos Adriana Maria Kakehasi Alessandra Maciel Almeida Pedro Ricardo Kömel Pimenta Juliana Alvares Teodoro Francisco de Assis Acurcio |
author_role |
author |
author2 |
Jéssica Barreto Ribeiro Dos Santos Adriana Maria Kakehasi Alessandra Maciel Almeida Pedro Ricardo Kömel Pimenta Juliana Alvares Teodoro Francisco de Assis Acurcio |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Michael Ruberson Ribeiro da Silva Jéssica Barreto Ribeiro Dos Santos Adriana Maria Kakehasi Alessandra Maciel Almeida Pedro Ricardo Kömel Pimenta Juliana Alvares Teodoro Francisco de Assis Acurcio |
dc.subject.por.fl_str_mv |
Arthritis, psoriatic Comparative effectiveness research Adalimumab Etanercept Observational study [publication type] Minimal clinically important difference |
topic |
Arthritis, psoriatic Comparative effectiveness research Adalimumab Etanercept Observational study [publication type] Minimal clinically important difference Artrite psoriásica Pesquisa comparativa da efetividade Adalimumab Etanercepte Estudo observacional Diferença mínima clinicamente importante |
dc.subject.other.pt_BR.fl_str_mv |
Artrite psoriásica Pesquisa comparativa da efetividade Adalimumab Etanercepte Estudo observacional Diferença mínima clinicamente importante |
description |
BACKGROUND: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects multiple joints. It is associated with psoriasis and treated with synthetic and biologic drugs. OBJECTIVE: The objective of this study was to assess the outcomes of patients who received biologic therapy with tumor necrosis factor (TNF) inhibitors in terms of effectiveness, safety, functionality, and quality of life. DESIGN AND SETTING: A prospective observational study was performed at a single center in Belo Horizonte, Brazil. METHODS: Patients with PsA who received their first TNF inhibitor treatment were followed up for 12 months. Disease activity was measured using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Clinical Disease Activity Index (CDAI). Functionality was measured using the Health Questionnaire Assessment (HAQ), and quality of life was evaluated using the European Quality of Life Five Dimensions (EQ-5D). Multiple linear regression was used to identify predictors of the clinical response at 12 months. RESULTS: A total of 143 patients treated with adalimumab or etanercept were evaluated. Most of the clinical measures were significantly improved at 12 months. However, 31%–51% of the patients did not achieve good clinical control. No differences were observed between adalimumab and etanercept, except for poor functionality at 12 months among patients treated with etanercept. The main predictors of a worse clinical response were female sex, etanercept use, poor functionality, or lower quality of life at baseline. The main adverse reactions were alopecia, headache, injection site reaction, sinusitis, flu, dyslipidemia, and infections. CONCLUSION: TNF inhibitor therapy was effective and safe. However, despite improvements in clinical measures, most patients did not achieve satisfactory control of the disease. |
publishDate |
2022 |
dc.date.issued.fl_str_mv |
2022 |
dc.date.accessioned.fl_str_mv |
2023-11-06T20:49:44Z |
dc.date.available.fl_str_mv |
2023-11-06T20:49:44Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/60534 |
dc.identifier.doi.pt_BR.fl_str_mv |
https://doi.org/10.1590/1516-3180.2021.0434.R1.22022022 |
dc.identifier.issn.pt_BR.fl_str_mv |
1806-9460 |
dc.identifier.orcid.pt_BR.fl_str_mv |
http://orcid.org/0000-0003-2550-7249 http://orcid.org/0000-0002-5528-0658 http://orcid.org/0000-0001-9411-7493 http://orcid.org/0000-0003-0138-9401 http://orcid.org/0000-0003-4024-0108 http://orcid.org/0000-0002-0210-0721 http://orcid.org/0000-0002-5880-5261 |
url |
https://doi.org/10.1590/1516-3180.2021.0434.R1.22022022 http://hdl.handle.net/1843/60534 http://orcid.org/0000-0003-2550-7249 http://orcid.org/0000-0002-5528-0658 http://orcid.org/0000-0001-9411-7493 http://orcid.org/0000-0003-0138-9401 http://orcid.org/0000-0003-4024-0108 http://orcid.org/0000-0002-0210-0721 http://orcid.org/0000-0002-5880-5261 |
identifier_str_mv |
1806-9460 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Sao Paulo Medical Journal |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.publisher.initials.fl_str_mv |
UFMG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
FAR - DEPARTAMENTO DE FARMÁCIA SOCIAL MED - DEPARTAMENTO DE APARELHO LOCOMOTOR MED - DEPARTAMENTO DE CLÍNICA MÉDICA |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/60534/1/License.txt https://repositorio.ufmg.br/bitstream/1843/60534/2/First-line%20biologic%20therapy%20with%20tumor%20necrosis%20factor%20inhibitors%20for%20psoriatic%20arthritis_%20a%20prospective%20observational%20study.pdf |
bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 4b4709a03b6447669df31e2cc2ba7aa7 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
|
_version_ |
1803589191351664640 |